• Something wrong with this record ?

Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review

M. Turjap, M. Pelcová, J. Gregorová, P. Šmak, H. Martin, J. Štingl, O. Peš, J. Juřica

. 2024 ; 46 (3) : 321-331. [pub] 20240430

Language English Country United States

Document type Systematic Review, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013640

BACKGROUND: Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib. This review aimed to establish whether sufficient evidence exists for the routine or selective therapeutic drug monitoring of pazopanib in adult patients with approved indications. METHODS: A systematic search of the PubMed and Web of Science databases using search terms related to pazopanib and therapeutic drug monitoring yielded 186 and 275 articles, respectively. Ten articles associated with treatment outcomes or toxicity due to drug exposure were selected for review. RESULTS: The included studies were evaluated to determine the significance of the relationship between drug exposure/Ctrough and treatment outcomes and between drug exposure and toxicity. A relationship between exposure and treatment outcomes was observed in 5 studies, whereas the trend was nonsignificant in 4 studies. A relationship between exposure and toxicity was observed in 6 studies, whereas 2 studies did not find a significant relationship; significance was not reported in 3 studies. CONCLUSIONS: Sufficient evidence supports the therapeutic drug monitoring of pazopanib in adult patients to improve its efficacy and/or safety in the approved indications.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013640
003      
CZ-PrNML
005      
20240905133550.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FTD.0000000000001206 $2 doi
035    __
$a (PubMed)38723115
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Turjap, Miroslav $u Department of Clinical Pharmacy, University Hospital Ostrava, Ostrava, Czech Republic
245    10
$a Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review / $c M. Turjap, M. Pelcová, J. Gregorová, P. Šmak, H. Martin, J. Štingl, O. Peš, J. Juřica
520    9_
$a BACKGROUND: Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib. This review aimed to establish whether sufficient evidence exists for the routine or selective therapeutic drug monitoring of pazopanib in adult patients with approved indications. METHODS: A systematic search of the PubMed and Web of Science databases using search terms related to pazopanib and therapeutic drug monitoring yielded 186 and 275 articles, respectively. Ten articles associated with treatment outcomes or toxicity due to drug exposure were selected for review. RESULTS: The included studies were evaluated to determine the significance of the relationship between drug exposure/Ctrough and treatment outcomes and between drug exposure and toxicity. A relationship between exposure and treatment outcomes was observed in 5 studies, whereas the trend was nonsignificant in 4 studies. A relationship between exposure and toxicity was observed in 6 studies, whereas 2 studies did not find a significant relationship; significance was not reported in 3 studies. CONCLUSIONS: Sufficient evidence supports the therapeutic drug monitoring of pazopanib in adult patients to improve its efficacy and/or safety in the approved indications.
650    12
$a indazoly $x terapeutické užití $7 D007191
650    _2
$a lidé $7 D006801
650    12
$a sulfonamidy $x terapeutické užití $x farmakokinetika $7 D013449
650    12
$a pyrimidiny $x terapeutické užití $x farmakokinetika $7 D011743
650    12
$a monitorování léčiv $x metody $7 D016903
650    12
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    12
$a sarkom $x farmakoterapie $7 D012509
650    12
$a nádory ledvin $x farmakoterapie $7 D007680
650    12
$a inhibitory angiogeneze $x terapeutické užití $x farmakokinetika $7 D020533
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pelcová, Marta $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Gregorová, Jana $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Šmak, Pavel $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Martin, Hiroko $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Štingl, Jan $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Peš, Ondřej $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Juřica, Jan $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Masaryk Memorial Cancer Institute, Brno, Czech Republic; and $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000202576711 $7 xx0085543
773    0_
$w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 46, č. 3 (2024), s. 321-331
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38723115 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133544 $b ABA008
999    __
$a ok $b bmc $g 2143437 $s 1225506
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 46 $c 3 $d 321-331 $e 20240430 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options